2,3,4,9-四氢-1H-咔唑-2-羧酸 | 37964-14-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2,3,4,9-四氢-1H-咔唑-2-羧酸
• 英文名称: 1,2,3,4-Tetrahydro-carbazol-2-carbonsaeure
• 英文别名: 1,2,3,4-tetrahydro-carbazole-2-carboxylic acid；2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid
• CAS: 37964-14-0
• 化学式: C₁₃H₁₃NO₂
• 分子量: 215.252
• InChiKey: VSIDDKKWZMIYEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为产物：
  描述：

  2-羟基对苯二甲酸 在 sodium hydroxide 、 mineral acid 、 水 作用下， 生成 2,3,4,9-四氢-1H-咔唑-2-羧酸
  参考文献：
  名称：

  Baeyer; Tutein, Chemische Berichte, 1889, vol. 22, p. 2183

  摘要：

  DOI：

文献信息

• Fused indolecarboxamides: dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation

  公开号：US05892041A1

  公开（公告）日：1999-04-06

  Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: ##STR2## represents an aromatic or alicyclic ring; R.sub.1 and R.sub.2 are the same or different and represent hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C.sub.1 -C.sub.6 alkoxy, --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1 or 2; or R.sub.1 and R.sub.2 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C.sub.1 -C.sub.6 alkyl; R.sub.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, or --COR'" where R'" is C.sub.1 -C.sub.6 alkyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention are useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

  本发明揭示了以下化合物的结构：##STR1##或其药学上可接受的酸盐，其中：##STR2##代表芳香或脂环；R.sub.1和R.sub.2相同或不同，代表氢、C.sub.1 -C.sub.6烷基、卤素、羟基、氨基、氰基、硝基、三氟甲基、三氟甲氧基、C.sub.1 -C.sub.6烷氧基、--O.sub.2CR'、--NHCOR'、--COR'、--SO.sub.mR'，其中R'是C.sub.1 -C.sub.6烷基，m为0、1或2；或R.sub.1和R.sub.2独立地代表--CONR'R"或--NR'R"，其中R'和R"独立地代表氢或C.sub.1 -C.sub.6烷基；R.sub.3为氢、C.sub.1 -C.sub.6烷基，或--COR'"，其中R'"为C.sub.1 -C.sub.6烷基；R.sub.4为氢或C.sub.1 -C.sub.6烷基；R代表氨基烷基基团，这些化合物可用于治疗情感障碍，如精神分裂症、抑郁症、阿尔茨海默病、帕金森病和肌张力障碍等运动障碍，以及对多巴胺受体阻滞有反应的其他障碍，如物质滥用和强迫症。此外，本发明的化合物可用于治疗与传统神经阻滞剂使用相关的外围神经副作用。
• TRICYCLIC CYTOPROTECTIVE COMPOUNDS
  申请人：Wulfert Ernst

  公开号：US20090259043A1

  公开（公告）日：2009-10-15

  Compounds of formula (I): [in which: X is a group of formula >CR 1 R 2 or >SO 2 ; Y is a group of formula >NH or >CR 1 R 2 ; Z is a group of formula >C═O or >CH 2 or a direct bond; R 1 is hydrogen and R 2 is hydrogen, carboxy or hydroxy; or R 1 and R 2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R 3 is hydrogen or lower alkyl; R 4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R 5 is hydrogen, lower alkyl or halogen; R 6 is hydrogen, lower alkoxy or carboxy; R 7 and R 8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

  式(I)的化合物：[其中：X是公式>CR1R2或>SO2的基团；Y是公式>NH或>CR1R2的基团；Z是公式>C═O或>CH2或直接键的基团；R1是氢原子，R2是氢原子，羧基或羟基；或R1和R2一起代表氧代基、甲亚基二氧基基团或羟基亚胺基团；R3是氢原子或较低的烷基；R4代表两个氢原子或氧代基或羟基亚胺基团；R5是氢原子、较低的烷基或卤素；R6是氢原子、较低的烷氧基或羧基；R7和R8均为氢原子、较低的烷基或卤素；以及其药学上可接受的盐和酯，可用于治疗或预防急性或慢性神经退行性疾病或病症，如阿尔茨海默病、帕金森病、亨廷顿舞蹈病、多发性硬化症或急性缺血事件的后遗症，如心脏病发作、中风或头部损伤，并用于保护外周器官组织免受缺血性损伤。
• Tricyclic Cytoprotective Compounds
  申请人：Wulfert Ernst

  公开号：US20080146644A1

  公开（公告）日：2008-06-19

  Compounds of formula (I): [in which: X is a group of formula >CR 1 R 2 or >SO 2 ; Y is a group of formula >NH or >CR 1 R 2 ; Z is a group of formula >C═O or >CH 2 or a direct bond; R 1 is hydrogen and R 2 is hydrogen, carboxy or hydroxy; or R 1 and R 2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R 3 is hydrogen or lower alkyl; R 4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R 5 is hydrogen, lower alkyl or halogen; R 6 is hydrogen, lower alkoxy or carboxy; R 7 and R 8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

  化合物的公式 (I)：[其中：X 是公式 >CR1R2 或 >SO2 的基团；Y 是公式 >NH 或 >CR1R2 的基团；Z 是公式 >C═O 或 >CH2 或直接键；R1 是氢原子，R2 是氢原子，羧基或羟基；或者 R1 和 R2 一起表示一个氧代基团、一个甲二氧基基团或一个羟肟基团；R3 是氢原子或低碳基；R4 表示两个氢原子，或一个氧代基团或羟肟基团；R5 是氢原子、低碳基或卤素；R6 是氢原子、低烷氧基或羧基；R7 和 R8 分别是氢原子、低碳基或卤素；以及其药学上可接受的盐和酯，可用于治疗或预防急性或慢性神经退行性疾病或病症，如阿尔茨海默病、帕金森病、亨廷顿舞蹈病、多发性硬化症或急性缺血事件的后遗症，如心脏病发作、中风或头部损伤，并保护外围器官组织免受缺血损伤。
• [EN] TRICYCLIC CYTOPROTECTIVE COMPOUNDS<br/>[FR] COMPOSES CYTOPROTECTEURS TRICYCLIQUES
  申请人：HUNTER FLEMING LTD

  公开号：WO2006082409A3

  公开（公告）日：2006-12-14
• FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
  申请人：NEUROGEN CORPORATION

  公开号：EP0923574A1

  公开（公告）日：1999-06-23